Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carboplatin is ototoxic.

I C Kennedy1, B M Fitzharris, B M Colls

  • 1Department of Clinical Oncology, Christchurch Hospital, New Zealand.

Cancer Chemotherapy and Pharmacology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two cases of severe liver injury possibly related to 5-fluorouracil and calcium folinate.

Internal medicine journal·2007
Same author

Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital.

Internal medicine journal·2005
Same author

Hyponatremia and seizures after bowel preparation: report of three cases.

Diseases of the colon and rectum·2005
Same author

Guillain-Barré syndrome and hyponatraemia.

Internal medicine journal·2004
Same author

Oncology service correspondence: do we communicate?

Australasian radiology·2003
Same author

Guillain-Barré syndrome and hyponatraemia.

Internal medicine journal·2003
Same journal

Off-target anti-leukemic effects of antibiotics: mechanisms and therapeutic insights.

Cancer chemotherapy and pharmacology·2026
Same journal

The use of pharmacodynamic results for recommended phase II decision making in oncology clinical trials.

Cancer chemotherapy and pharmacology·2026
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
See all related articles

Carboplatin (CBDCA) can cause hearing loss, but significant deafness is rare with standard doses. Routine hearing tests are likely unnecessary, though caution is advised for high doses or combined therapies.

Area of Science:

  • Oncology
  • Ototoxicology
  • Pharmacology

Background:

  • Carboplatin is a widely used chemotherapy agent.
  • Ototoxicity is a known potential side effect of platinum-based chemotherapeutics.

Purpose of the Study:

  • To assess the ototoxic potential of carboplatin (cis-diammine-1,1-cyclobutane dicarboxylate platinum(II); CBDCA).
  • To determine the incidence and characteristics of carboplatin-induced hearing loss.

Main Methods:

  • Pure-tone audiometry (PTA) was performed on 27 patients before and after carboplatin administration.
  • Ototoxicity was defined as a ≥30 dB increase in auditory thresholds.
  • Hearing thresholds were evaluated at various frequencies, particularly 8,000 Hz.

Main Results:

Related Experiment Videos

  • Ototoxicity was identified in 19% of assessed carboplatin doses.
  • Hearing loss was cumulative, dose-dependent, and most pronounced at 8,000 Hz.
  • Older patients were more prone to ototoxicity; other factors were not reliable predictors.

Conclusions:

  • Carboplatin exhibits ototoxic properties, but clinically significant deafness is uncommon with conventional dosing.
  • Routine audiometric monitoring may not be necessary for standard carboplatin regimens.
  • Caution is recommended for high-dose carboplatin, prolonged treatment, or concurrent ototoxic agents.